Chinese expert consensus on the correlation between intestinal microecology and hematopoietic stem cell transplantation （2026 Edition）

doi:10.3760/cma.j.cn371439-20260308-00054

Abstract

Abstract:

Hematopoietic stem cell transplantation （HSCT） affects intestinal flora homeostasis， and intestinal microecology may also affect the prognosis of HSCT patients through multiple mechanisms. To gain a deeper understanding of intestinal microecology and HSCT to address the key issues of correlation， and to learn and absorb the latest research progress， the Tumor and Microecology Committee of the Chinese Anti-Cancer Association organized relevant experts to revise on the basis of the "Chinese expert consensus on the correlation between intestinal microecology and hematopoietic stem cell transplantation " （2021 Edition） and proposed the "Chinese expert consensus on the correlation between intestinal microecology and hematopoietic stem cell transplantation （2026 Edition）". This consensus， based on the latest domestic and international literature and combined with the latest technology and research in the discipline， presents 9 recommendations regarding issues such as the indications of intestinal microecology in hematopoietic stem cell transplantation， for clinicians to refer to in practice. This consensus can not only provide practical guidance for clinicians， but also lay a foundation for further in-depth research in the fields of oncology and microecology.

Key words: Gastrointestinal microbiome, Hematopoietic stem cell transplantation, Consensus, Correlation

Tumor and Microecology Committee of the Chinese Anti-Cancer Association. Chinese expert consensus on the correlation between intestinal microecology and hematopoietic stem cell transplantation （2026 Edition）[J]. Journal of International Oncology, 2026, 53(7): 388-397.

References 68

[1]	中国抗癌协会肿瘤与微生态专业委员会. 肠道微生态与造血干细胞移植相关性中国专家共识[J]. 国际肿瘤学杂志, 2021, 48(3): 129-135. DOI: 10.3760/cma.j.cn371439-20210202-00027.
[2]	郭智, 刘晓萱. 肠菌移植在肿瘤治疗中的应用和挑战[J/OL]. 中国医学前沿杂志(电子版), 2025, 17(7): 91-98. DOI: 10.3760/cma.j.issn.1674-7372.2025.07.102.
[3]	Dai W, Chen X, Zhou H, et al. Microbiota modulation for infectious complications following allogeneic hematopoietic stem cell transplan-tation in pediatric hematological malignancies[J]. Front Pediatr, 2025, 13: 1509612. DOI: 10.3389/fped.2025.1509612.
[4]	Koliarakis I, Psaroulaki A, Nikolouzakis TK, et al. Intestinal microbiota and colorectal cancer: a new aspect of research[J]. J BUON, 2018, 23(5): 1216-1234. pmid: 30512251
[5]	中国抗癌协会肿瘤与微生态专业委员会. 肠道微生态与肿瘤治疗相关消化系统并发症管理中国专家共识[J]. 国际肿瘤学杂志, 2022, 49(12): 711-717. DOI: 10.3760/cma.j.cn371439-20220911-00140.
[6]	Storb R, Prentice RL, Buckner CD, et al. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment[J]. N Engl J Med, 1983, 308(6): 302-307. DOI: 10.1056/NEJM198302103080602.
[7]	Jenq RR, Taur Y, Devlin SM, et al. Intestinal Blautia is associated with reduced death from graft-versus-host disease[J]. Biol Blood Marrow Transplant, 2015, 21(8): 1373-1383. DOI: 10.1016/j.bbmt.2015.04.016.
[8]	González-Rico C, Hernández M, Rodríguez-Grande J, et al. Changes in the bacterial profile and diversity of the gut microbiota in allogeneic hematopoietic stem cell transplant recipients[J]. Int J Infect Dis, 2025, 161: 108117. DOI: 10.1016/j.ijid.2025.108117.
[9]	刘晓萱, 肖建红, 刘宁, 等. 受者移植前肠道微生物多样性对造血干细胞移植临床结局的影响[J]. 中国医学前沿杂志(电子版), 2025, 17(10): 44-53. DOI: 10.12037/YXQY.2025.10-07.
[10]	Azhar Ud Din M, Lin Y, Lyu C, et al. Advancing therapeutic strategies for graft-versus-host disease by targeting gut microbiome dynamics in allogeneic hematopoietic stem cell transplantation: current evidence and future directions[J]. Mol Med, 2025, 31(1): 2. DOI: 10.1186/s10020-024-01060-x. pmid: 39754054
[11]	Yang K, Du J, Huang F, et al. Fecal microbiota transplantation for refractory chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation: a pilot open-label, non-placebo-controlled study[J]. BMC Med, 2025, 23(1): 498. DOI: 10.1186/s12916-025-04336-z. pmid: 40859356
[12]	Xiang X, He M, Li X, et al. Efficacy and safety of oropharyngeal probiotic BP-OM1 on respiratory infection-like symptoms among patients with lymphoma after autologous hematopoietic stem cell transplantation: a multicenter randomized controlled pilot study[J]. Transplant Proc, 2025, 57(4): 627-637. DOI: 10.1016/j.transproceed.2025.02.042.
[13]	郭智, 刘晓东, 杨凯, 等. allo-HSCT并使用高剂量环磷酰胺诱导免疫耐受治疗重型再生障碍性贫血[J]. 中华器官移植杂志, 2015, 36(6): 356-361. DOI: 10.3760/cma.j.issn.0254-1785.2015.06.008.
[14]	Hamers AAJ, Joshi SK, Pillai AB. Innate immune determinants of graft-versus-host disease and bidirectional immune tolerance in allogeneic transplantation[J]. OBM Transplant, 2019, 3(1): 44. DOI: 10.21926/obm.transplant.1901044.
[15]	郭智, 舒榕, 王强. CD4⁺CD25⁺调节性T细胞在造血干细胞移植后诱导免疫耐受的作用[J]. 生命的化学, 2020, 40(1): 75-79. DOI: 10.13488/j.smhx.20190266.
[16]	中国抗癌协会肿瘤整体评估专业委员会, 中国抗癌协会肿瘤与微生态专业委员会, 广东省预防医学会血液肿瘤防治专业委员会. 造血干细胞移植临床实践整体评估中国专家共识(2025年版)[J]. 中国医学前沿杂志(电子版), 2025, 17(6): 1-13. DOI: 10.12037/YXQY.2025.06-01.
[17]	Li A, Bowen JM, Ball IA, et al. Autologous faecal microbiota transplantation to improve outcomes of haematopoietic stem cell transplantation: results of a single-centre feasibility study[J]. Biomedicines, 2023, 11(12): 3274. DOI: 10.3390/biomedicines11123274.
[18]	Guo Z, He M, Shao L, et al. The role of fecal microbiota transplan-tation in the treatment of acute graft-versus-host disease[J]. J Cancer Res Ther, 2024, 20(7): 1964-1973. DOI: 10.4103/jcrt.jcrt_952_23.
[19]	Lindner S, Peled JU. Update in clinical and mouse microbiota research in allogeneic hematopoietic cell transplantation[J]. Curr Opin Hematol, 2020, 27(6): 360-367. DOI: 10.1097/MOH.0000000000000616. pmid: 33003084
[20]	Wang Q, Lei Y, Wang J, et al. Expert consensus on the relevance of intestinal microecology and hematopoietic stem cell transplantation[J]. Clin Transplant, 2024, 38(1): e15186. DOI: 10.1111/ctr.15186.
[21]	Wang Q, He M, Liang J, et al. Chinese guidelines for integrated diagnosis and treatment of intestinal microecology technologies in tumor application (2024 edition)[J]. J Cancer Res Ther, 2024, 20(4): 1130-1140. DOI: 10.4103/jcrt.jcrt_32_24.
[22]	Leardini D, Roberto M, Roggiani S, et al. Hematopoietic stem cell transplantation disrupts age-related gut microbiota signatures in pediatric and adult recipients[J]. Bone Marrow Transplant, 2025, 60(12): 1611-1621. DOI: 10.1038/s41409-025-02713-z.
[23]	Jørgensen M, Nørgaard JC, Ilett EE, et al. Metabolic potential of the gut microbiome is significantly impacted by conditioning regimen in allogeneic hematopoietic stem cell transplantation recipients[J]. Int J Mol Sci, 2022, 23(19): 11115. DOI: 10.3390/ijms231911115.
[24]	Tanaka JS, Young RR, Heston SM, et al. Anaerobic antibiotics and the risk of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation[J]. Biol Blood Marrow Transplant, 2020, 26(11): 2053-2060. DOI: 10.1016/j.bbmt.2020.07.011.
[25]	Weber D, Jenq RR, Peled JU, et al. Microbiota disruption induced by early use of broad-spectrum antibiotics is an independent risk factor of outcome after allogeneic stem cell transplantation[J]. Biol Blood Marrow Transplant, 2017, 23(5): 845-852. DOI: 10.1016/j.bbmt.2017.02.006.
[26]	Shono Y. Gut microbiota and graft-versus-host disease: broad-spectrum antibiotic use increases post-allogeneic hematopoietic stem cell transplant graft-versus-host disease-related mortality[J]. Rinsho Ketsueki, 2017, 58(7): 835-842. DOI: 10.11406/rinketsu.58.835. pmid: 28781282
[27]	Zając-Spychała O, Wachowiak J, Pieczonka A, et al. Bacterial infections in pediatric hematopoietic stem cell transplantation recipients: incidence, epidemiology, and spectrum of pathogens: report of the polish pediatric group for hematopoietic stem cell transplantation[J]. Transpl Infect Dis, 2016, 18(5): 690-698. DOI: 10.1111/tid.12581. pmid: 27479544
[28]	Schuster MG, Cleveland AA, Dubberke ER, et al. Infections in hematopoietic cell transplant recipients: results from the Organ Transplant Infection Project, a multicenter, prospective, cohort study[J]. Open Forum Infect Dis, 2017, 4(2): ofx050. DOI: 10.1093/ofid/ofx050.
[29]	Lin Z, Iqbal Z, Ortiz JF, et al. Fecal microbiota transplantation in recurrent clostridium difficile infection: is it superior to other conventional methods?[J]. Cureus, 2020, 12(8): e9653. DOI: 10.7759/cureus.9653.
[30]	Luo Y, Zhang S, Shang H, et al. Prevalence of clostridium difficile infection in the hematopoietic transplantation setting: update of systematic review and meta-analysis[J]. Front Cell Infect Microbiol, 2022, 12: 801475. DOI: 10.3389/fcimb.2022.801475.
[31]	Sanchez E, Krantz EM, Escobar ZK, et al. Epidemiology and outcomes of recurrent C difficile infection among hematopoietic cell transplant recipients: a single-center, retrospective 10-year study[J]. Open Forum Infect Dis, 2024, 11(10): ofae570. DOI: 10.1093/ofid/ofae570.
[32]	Vaughn JL, Balada-Llasat JM, Lamprecht M, et al. Detection of toxigenic clostridium difficile colonization in patients admitted to the hospital for chemotherapy or haematopoietic cell transplantation[J]. J Med Microbiol, 2018, 67(7): 976-981. DOI: 10.1099/jmm.0.000774. pmid: 29863458
[33]	Salamonowicz M, Ociepa T, Frączkiewicz J, et al. Incidence, course, and outcome of clostridium difficile infection in children with hematological malignancies or undergoing hematopoietic stem cell transplantation[J]. Eur J Clin Microbiol Infect Dis, 2018, 37(9): 1805-1812. DOI: 10.1007/s10096-018-3316-5.
[34]	Zhou B, Yuan Y, Zhang S, et al. Intestinal flora and disease mutually shape the regional immune system in the intestinal tract[J]. Front Immunol, 2020, 11: 575. DOI: 10.3389/fimmu.2020.00575. pmid: 32318067
[35]	Vobořil M, Brabec T, Dobeš J, et al. Toll-like receptor signaling in thymic epithelium controls monocyte-derived dendritic cell recruitment and Treg generation[J]. Nat Commun, 2020, 11(1): 2361. DOI: 10.1038/s41467-020-16081-3. pmid: 32398640
[36]	Jang GY, Lee JW, Kim YS, et al. Interactions between tumor-derived proteins and Toll-like receptors[J]. Exp Mol Med, 2020, 52(12): 1926-1935. DOI: 10.1038/s12276-020-00540-4.
[37]	Jonsson H, Hugerth LW, Sundh J, et al. Genome sequence of segmented filamentous bacteria present in the human intestine[J]. Commun Biol, 2020, 3(1): 485. DOI: 10.1038/s42003-020-01214-7. pmid: 32887924
[38]	Masetti R, Leardini D, Muratore E, et al. Gut microbiota diversity before allogeneic hematopoietic stem cell transplantation as a predictor of mortality in children[J]. Blood, 2023, 142(16): 1387-1398. DOI: 10.1182/blood.2023020026. pmid: 37856089
[39]	Han L, Zhang H, Ma P, et al. Intestinal microbiota score could predict survival following allogeneic hematopoietic stem cell transplantation[J]. Ann Hematol, 2022, 101(6): 1283-1294. DOI: 10.1007/s00277-022-04817-8.
[40]	Baumgartner A, Bargetzi A, Zueger N, et al. Revisiting nutritional support for allogeneic hematologic stem cell transplantation—a systematic review[J]. Bone Marrow Transplant, 2017, 52(4): 506-513. DOI: 10.1038/bmt.2016.310.
[41]	Liu P, Wang B, Yan X, et al. Comprehensive evaluation of nutritional status before and after hematopoietic stem cell transplantation in 170 patients with hematological diseases[J]. Chin J Cancer Res, 2016, 28(6): 626-633. DOI: 10.21147/j.issn.1000-9604.2016.06.09.
[42]	Ilett EE, Jørgensen M, Noguera-Julian M, et al. Associations of the gut microbiome and clinical factors with acute GVHD in allogeneic HSCT recipients[J]. Blood Adv, 2020, 4(22): 5797-5809. DOI: 10.1182/bloodadvances.2020002677. pmid: 33232475
[43]	Fredricks DN. The gut microbiota and graft-versus-host disease[J]. J Clin Invest, 2019, 129(5): 1808-1817. DOI: 10.1172/JCI125797. pmid: 31042160
[44]	Yazdandoust E, Hajifathali A, Roshandel E, et al. Gut microbiota intervention by pre and probiotics can induce regulatory T cells and reduce the risk of severe acute GVHD following allogeneic hematopoietic stem cell transplantation[J]. Transpl Immunol, 2023, 78: 101836. DOI: 10.1016/j.trim.2023.101836.
[45]	Yoshifuji K, Inamoto K, Kiridoshi Y, et al. Prebiotics protect against acute graft-versus-host disease and preserve the gut microbiota in stem cell transplantation[J]. Blood Adv, 2020, 4(19): 4607-4617. DOI: 10.1182/bloodadvances.2020002604. pmid: 32991720
[46]	Kusakabe S, Fukushima K, Yokota T, et al. Enterococcus: a predictor of ravaged microbiota and poor prognosis after allogeneic hematopoietic stem cell transplantation[J]. Biol Blood Marrow Transplant, 2020, 26(5): 1028-1033. DOI: 10.1016/j.bbmt.2020.01.019.
[47]	Shono Y, van den Brink MRM. Gut microbiota injury in allogeneic haematopoietic stem cell transplantation[J]. Nat Rev Cancer, 2018, 18(5): 283-295. DOI: 10.1038/nrc.2018.10. pmid: 29449660
[48]	Parco S, Benericetti G, Vascotto F, et al. Microbiome and diversity indices during blood stem cells transplantation—new perspectives?[J]. Cent Eur J Public Health, 2019, 27(4): 335-339. DOI: 10.21101/cejph.a5393.
[49]	Zhang F, Zuo T, Yeoh YK, et al. Longitudinal dynamics of gut bacteriome, mycobiome and virome after fecal microbiota transplantation in graft-versus-host disease[J]. Nat Commun, 2021, 12(1): 65. DOI: 10.1038/s41467-020-20240-x. pmid: 33397897
[50]	Ladas EJ, Bhatia M, Chen L, et al. The safety and feasibility of probiotics in children and adolescents undergoing hematopoietic cell transplantation[J]. Bone Marrow Transplant, 2016, 51(2): 262-266. DOI: 10.1038/bmt.2015.275.
[51]	Han H, Yan H, King KY. Broad-spectrum antibiotics deplete bone marrow regulatory T cells[J]. Cells, 2021, 10(2): 277. DOI: 10.3390/cells10020277.
[52]	Blaser MJ. Antibiotic use and its consequences for the normal microbiome[J]. Science, 2016, 352(6285): 544-545. DOI: 10.1126/science.aad9358. pmid: 27126037
[53]	Pession A, Zama D, Muratore E, et al. Fecal microbiota transplan-tation in allogeneic hematopoietic stem cell transplantation recipients: a systematic review[J]. J Pers Med, 2021, 11(2): 100. DOI: 10.3390/jpm11020100.
[54]	Lee YJ, Arguello ES, Jenq RR, et al. Protective factors in the intestinal microbiome against clostridium difficile infection in recipients of allogeneic hematopoietic stem cell transplantation[J]. J Infect Dis, 2017, 215(7): 1117-1123. DOI: 10.1093/infdis/jix011. pmid: 28498996
[55]	中华医学会血液学分会干细胞应用学组. 异基因造血干细胞移植急性移植物抗宿主病诊断与治疗中国专家共识(2024年版)[J]. 中华血液学杂志, 2024, 45(6): 525-533. DOI: 10.3760/cma.j.cn121090-20240608-00214.
[56]	Schoemans HM, Lee SJ, Ferrara JL, et al. EBMT-NIH-CIBMTR Task Force position statement on standardized terminology and guidance for graft-versus-host disease assessment[J]. Bone Marrow Transplant, 2018, 53(11): 1401-1415. DOI: 10.1038/s41409-018-0204-7.
[57]	Penack O, Marchetti M, Aljurf M, et al. Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation[J]. Lancet Haematol, 2024, 11(2): e147-e159. DOI: 10.1016/S2352-3026(23)00342-3.
[58]	Spindelboeck W, Schulz E, Uhl B, et al. Repeated fecal microbiota transplantations attenuate diarrhea and lead to sustained changes in the fecal microbiota in acute, refractory gastrointestinal graft-versus-host disease[J]. Haematologica, 2017, 102(5): e210-e213. DOI: 10.3324/haematol.2016.154351.
[59]	Kakihana K, Fujioka Y, Suda W, et al. Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut[J]. Blood, 2016, 128(16): 2083-2088. DOI: 10.1182/blood-2016-05-717652. pmid: 27461930
[60]	Goloshchapov OV, Chukhlovin AB, Bakin EA, et al. Fecal microbiota transplantation for graft-versus-host disease in children and adults: methods, clinical effects, safety[J]. Ter Arkh, 2020, 92(7): 43-54. DOI: 10.26442/00403660.2020.07.000773. pmid: 33346444
[61]	Qiao X, Biliński J, Wang L, et al. Safety and efficacy of fecal microbiota transplantation in the treatment of graft-versus-host disease[J]. Bone Marrow Transplantation 2023, 58(1): 10-19. DOI: 10.1038/s41409-022-01824-1.
[62]	van Lier YF, Davids M, Haverkate NJE, et al. Donor fecal microbiota transplantation ameliorates intestinal graft-versus-host disease in allogeneic hematopoietic cell transplant recipients[J]. Sci Transl Med, 2020, 12(556): eaaz8926. DOI: 10.1126/scitranslmed.aaz8926.
[63]	Malard F, Loschi M, Huynh A, et al. Pooled allogeneic faecal microbiota MaaT013 for steroid-resistant gastrointestinal acute graft-versus-host disease: a single-arm, multicentre phase 2 trial[J]. eClinicalMedicine, 2023, 62: 102111. DOI: 10.1016/j.eclinm.2023.102111.
[64]	Zhao Y, Li X, Zhou Y, et al. Safety and efficacy of fecal microbiota transplantation for grade Ⅳ steroid refractory GI-GVHD patients: interim results from FMT2017002 trial[J]. Front Immunol, 2021, 12: 678476. DOI: 10.3389/fimmu.2021.678476.
[65]	郭智, 王强. 肠菌移植制备和质控实验室标准化技术规范中国专家共识(2023版)[J]. 中国微生态学杂志, 2024, 36(6): 705-711. DOI: 10.13381/j.cnki.cjm.202406013.
[66]	中国抗癌协会肿瘤与微生态专业委员会, 湖北省免疫学会肿瘤与微生态专业委员会. 肠道微生态组学实验室标准化技术规范中国专家共识(2022版)[J]. 中华实验外科杂志, 2024, 41(8): 1873-1882. DOI: 10.3760/cma.j.cn421213-20220607-00428.
[67]	中国抗癌协会肿瘤与微生态专业委员会. 中国抗癌协会肠道微生态技术整合诊治指南(精简版)[J]. 中国肿瘤临床, 2023, 50(18): 919-927. DOI: 10.12354/j.issn.1000-8179.2023.20230913.
[68]	中国抗癌协会肿瘤与微生态专业委员会, 湖北省免疫学会肿瘤与微生态专业委员会. 肠菌移植应用于肿瘤治疗中国专家共识(2025年版)[J/OL]. 中国医学前沿杂志(电子版), 2025, 17(7): 1-14. DOI: 10.12037/YXQY.2025.07-01.